14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EW vs BAX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EW Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)
EW Overall Winner
6-Pillar Tally: EW 4 – 2 BAX
Matrix Metrics: EW 7 – 3 BAX
As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Baxter International Inc. (BAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas BAX carries 33.7/100 (SELL) at $25.57 (12.6x Forward P/E, 7.6% operating margin).
Composite vs. Pillar Nuance: While BAX currently prints a higher short-term Unified Composite Score (33.7/100 SELL vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 7.6% operating margin) and revenue trajectory (+10.5% vs. +5.0% YoY).
Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and BAX (33.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Medical Instruments & Supplies value chain with $13.3B market capitalization and 7.6% operating margin.
OpEx & R&D Reinvestment25.8% of Rev ($3.00B)
90D Engineering Disclosures0 Published
Investor FAQ EW vs BAX Key Questions & Quantitative Answers
As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Baxter International Inc. (BAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas BAX carries 33.7/100 (SELL) at $25.57 (12.6x Forward P/E, 7.6% operating margin). Composite vs. Pillar Nuance: While BAX currently prints a higher short-term Unified Composite Score (33.7/100 SELL vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 7.6% operating margin) and revenue trajectory (+10.5% vs. +5.0% YoY). Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and BAX (33.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with BAX at +5.0% YoY revenue growth and +36.8% YoY earnings growth on $11.6B TTM revenue (33.4% gross margin, 7.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EW cumulative revenue shifted +63.2% while BAX shifted +1.3%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 25.8% of Rev ($3.00B) (0 disclosures) for BAX.
BAX screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas BAX trades at 12.6x Forward P/E, 12.4x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (9.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus BAX (-9.0% ROE) capital efficiency.
In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, BAX carries 205.7% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 48% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.